tucidinostat

Ligand id: 8305

Name: tucidinostat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 97.11
Molecular weight 390.15
XLogP 3.6
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Chidamide was developed and tested in China, where it now has regulatory approval for the treatment of cancers. Preclinical studies have shown efficacy in various types of cancer, such as pancreatic cancer [4], colon cancer [3], hepatocellular carcinoma cells [5] and leukemias [2,6]. Phase I clinical trial results are reported in [1].
Mechanism Of Action and Pharmacodynamic Effects
Chidamide is an inhibitor of histone deacetylase (HDAC) activity, which increases acetylation of histone H3. This leads to downstream activation of the PI3K/Akt and MAPK/Ras signaling pathways and ultimately results in cell cycle arrest and apoptosis [3].